©The Author(s) 2019.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Table 3 Frequency of TYMS 5’UTR, 3’UTR genotypes
| Genotype | Total n (%) |
| TYMS 5’UTR | 130 (100) |
| 2R | 13 (10.0) |
| 2R/3R | 78 (60.0) |
| 2R/3RG | 34 (26.1) |
| 2R/3RG | 20 (15.4) |
| 2R/3RGLOH | 8 (6.2) |
| 2RLOH/3RG | 6 (4.6) |
| 2R/3RC | 44 (33.8) |
| 2R/3RC | 24 (18.5) |
| 2R/3RCLOH | 13 (10.0) |
| 2RLOH/3RC | 7 (5.4) |
| 3R | 39 (30.0) |
| 3RG | 10 (7.7) |
| 3RG/3RC | 20 (15.4) |
| 3RC | 9 (6.9) |
| TYMS 3’UTR | 130 (100) |
| ins/ins | 28 (21.5) |
| ins/LOH | 27 (20.8) |
| ins/del | 52 (40.0) |
| del/LOH | 7 (5.4) |
| del/del | 16 (12.3) |
- Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566
- URL: https://www.wjgnet.com/1948-5204/full/v11/i7/551.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.551